Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

[The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].

Federal service on surveillance in healthcare and social development (Roszdravnadzor).

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):86-92. Russian.

PMID:
21916162
2.

[Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].

Federal service on surveillance in healthcare and social development (Roszdravnadzor).

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):93-8. Russian. No abstract available.

PMID:
21916163
3.

[A possible effect of the immunomodulating therapy with beta-interferons and glatimer acetate on the development of thyroid disease in patients with multiple sclerosis].

Petrova LV, Boĭkova AN, Batysheva TT, Gusev EI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):58-67. Russian.

PMID:
21916158
4.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

5.

Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.

Katrych O, Simone TM, Azad S, Mousa SA.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):512-9. Review.

PMID:
19811446
6.

Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.

Mahurkar S, Suppiah V, O'Doherty C.

Autoimmun Rev. 2014 Feb;13(2):178-86. doi: 10.1016/j.autrev.2013.10.012. Epub 2013 Nov 2. Review. Erratum in: Autoimmun Rev. 2014 Dec;13(12):1243.

PMID:
24189284
7.

[Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].

Spirin NN, Kasatkin DS, Stepanov IO, Shipova EG, Baranova NS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(8):27-33. Russian.

PMID:
23096035
8.

[Quality of life of patients receiving long-term treatment with first-line disease-modifying drugs: results of a Russian multicenter study using MusiQoL].

Boĭko OV, Popova EV, Boĭko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(10 Pt 2):86-92. Russian.

PMID:
24300820
9.

Interferon beta and glatiramer acetate therapy.

McGraw CA, Lublin FD.

Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4. Review.

10.

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H.

Neurology. 2012 Sep 11;79(11):1130-5. doi: 10.1212/WNL.0b013e3182698c64. Epub 2012 Aug 29. Review.

11.

Editorial: the pitfalls of combination therapy.

Vermersch P.

Int MS J. 2006 Nov;13(3):75-6. No abstract available.

PMID:
17101074
12.

Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS; CombiRx Investigators.

Ann Neurol. 2013 Mar;73(3):327-40. doi: 10.1002/ana.23863. Epub 2013 Mar 11.

13.

The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.

Duddy M, Palace J.

Pract Neurol. 2016 Feb;16(1):4-6. doi: 10.1136/practneurol-2015-001209. Epub 2015 Oct 1. No abstract available.

PMID:
26430247
14.

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response.

Río J, Tintoré M, Sastre-Garriga J, Nos C, Castilló J, Tur C, Comabella M, Montalban X.

Eur J Neurol. 2012 Jun;19(6):899-904. doi: 10.1111/j.1468-1331.2011.03648.x. Epub 2012 Jan 31.

PMID:
22289050
15.

The use of interferon Beta and glatiramer acetate in multiple sclerosis.

Goodin DS.

Semin Neurol. 2013 Feb;33(1):13-25. doi: 10.1055/s-0033-1343792. Epub 2013 May 25. Review.

PMID:
23709209
16.

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.

PMID:
15623672
17.

[Multiple sclerosis in children and adolescents: history and current experience of immunomodulating treatment].

Bykova OV, Maslova OI, Guseva MR, Boĭko SIu, Totolian NA, Matveeva TA, Boĭko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(4):4-10. Review. Russian.

PMID:
15270293
18.

Comparative studies of glatiramer acetate and interferon beta.

Goodin D.

Int MS J. 2008 Jun;15(2):39-41.

PMID:
18782497
19.

Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.

Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J.

Curr Med Res Opin. 2007 Jun;23(6):1209-15. Epub 2007 Apr 23.

PMID:
17559722
20.

Supplemental Content

Support Center